Get started
Author

Sam Agresta

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
2017 · Eytan M. Stein, Courtney D. DiNardo, et al. · Blood · 1,508
Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
2018 · Courtney D. DiNardo, Eytan M. Stein, et al. · New England Journal of Medicine · 1,455
PDF
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
2013 · Fang Wang, Jeremy Travins, et al. · Science · 800
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
2015 · Courtney D. DiNardo, Farhad Ravandi, et al. · American Journal of Hematology · 321
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
2018 · Lynn Quek, Muriel D. David, et al. · Nature Medicine · 197
PDF
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
2014 · Andrew Kernytsky, Fang Wang, et al. · Blood · 172
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
2020 · William D. Tap, Victor M. Villalobos, et al. · Journal of Clinical Oncology · 165
Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
2014 · Darrell R. Borger, Lipika Goyal, et al. · Clinical Cancer Research · 138
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
2019 · Bin Fan, Ingo K. Mellinghoff, et al. · Investigational New Drugs · 94
PDF
AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies
2014 · Eytan M. Stein, Jessica K Altman, et al. · Blood · 90
Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate
2014 · Amir T. Fathi, Hossein Sadrzadeh, et al. · The Oncologist · 75
Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers
2018 · Hua Yang, Elizabeth Merica, et al. · Clinical Pharmacology in Drug Development · 58
Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study
2015 · Courtney DiNardo, Stéphane de Botton, et al. · Blood · 57
AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
2014 · Erica Hansen, Cyril Quivoron, et al. · Blood · 46
Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas
2015 · Howard Burris, Ingo Mellinghoff, et al. · Molecular Cancer Therapeutics · 36
Isocitrate dehydrogenase 1 and 2 mutations, 2‐hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia
2018 · Andrew M. Brunner, Donna S. Neuberg, et al. · Cancer · 34
PDF
Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects
2019 · Chandra Prakash, Bin Fan, et al. · Cancer Chemotherapy and Pharmacology · 24
Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
2017 · Courtney D. DiNardo, Stephane De Botton, et al. · Blood · 23
Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies
2015 · Bin Fan, Kha Le, et al. · Blood · 22
1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies
2014 · D.A. Pollyea, S. de Botton, et al. · European Journal of Cancer · 21
Actr-46. Ag120, a First-in-class Mutant Idh1 Inhibitor in Patients With Recurrent or Progressive Idh1 Mutant Glioma: Results From the Phase 1 Glioma Expansion Cohorts
2016 · Ingo K. Mellinghoff, Mehdi Touat, et al. · Neuro-Oncology · 20
PDF
AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model
2014 · Cyril Quivoron, Muriel David, et al. · Blood · 19
Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial
2015 · Yue Gao, Bin Fan, et al. · Blood · 6
Evaluation of Pharmacokinetic-Pharmacodynamic (PKPD) Relationship of an Oral, Selective, First-in-Class, Potent IDH2 Inhibitor, AG-221, from a Phase 1 Trial in Patients with Advanced IDH2 Mutant Positive Hematologic Malignancies
2014 · Bin Fan, Yue Chen, et al. · Blood · 6
Abstract 3116: AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model
2014 · Kate Ellwood-Yen, Fang Wang, et al. · Cancer Research · 6
Works count: 50
Citation count: 5,423
H-index: 20
I10-index: 22
Year
Topic
Type